Peking Union Medical College / Chinese Academy of Medical Sciences
北京协和医学院/中国医学科学院
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 45 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 3
- Research papers it led
- 45
- Trials it led
- 12
- Share of China's trials
- 2.0%
- Share of the world's papers
- 1.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- A MRI-based radiomics model predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
- Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.
- Application of multidimensional diffusion-weighted magnetic resonance imaging in nasopharyngeal carcinoma: a prospective study.
- The prognostic value of intra- and peritumoral habitat analysis in nasopharyngeal carcinoma: combining IVIM and ASL.
- Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
Trials on ClinicalTrials.gov6
- Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
- RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
- Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
- LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
- Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 200 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 12
- Research papers it led
- 200
- Trials it led
- 36
- Share of China's trials
- 6.3%
- Share of the world's papers
- 4.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
- Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
- First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
- Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial.
- The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.
Trials on ClinicalTrials.gov6
- Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
- Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
- Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
- Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
- Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
- Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 233 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 18
- Research papers it led
- 233
- Trials it led
- 48
- Share of China's trials
- 3.3%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis.
- Predictive factors of microvascular invasion in patients with intrahepatic mass-forming cholangiocarcinoma based on magnetic resonance images.
- A nomogram model to predict prognosis of patients with hepatoblastoma.
- Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial.
- Diagnostic value of whole-tumor apparent diffusion coefficient map radiomics analysis in predicting early recurrence of solitary hepatocellular carcinoma ≤ 5 cm.
Trials on ClinicalTrials.gov6
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
- Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Stomach cancer
胃癌Led 210 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 6
- Research papers it led
- 210
- Trials it led
- 40
- Share of China's trials
- 2.7%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial.
- Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study.
- Preoperative H. pylori Eradication Therapy Facilitates Precise Delineation in Early Gastric Cancer with Current H. pylori Infection.
- Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label
- Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible.
Trials on ClinicalTrials.gov6
- Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
- Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer
- Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
- A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
- Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
- Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Hepatoblastoma
肝母细胞瘤Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Papers it led3
- A nomogram model to predict prognosis of patients with hepatoblastoma.
- Analysis of risk factors for angiolymphatic invasion and establishment of a predictive nomogram for hepatoblastomas.
- Prognostic prediction of hepatoblastoma in children: development and validation of machine learning models-an SEER-based study.
Osteosarcoma
骨肉瘤Led 19 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 19
- Trials it led
- 1
- Share of China's trials
- 1.7%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Fine-needle aspiration cytology for the diagnosis of ewing's sarcoma in bone: a case report.
- Pulmonary artery osteosarcoma masquerading as pulmonary thromboembolism: the role of multimodality imaging.
- Osteosarcoma immunometabolism: emerging mechanisms and clinical implications.
- HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway.
- Chromoanagenesis in Osteosarcoma.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 7 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 1
- Share of China's trials
- 1.4%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Heterotopic Pancreas Mimicking Gastrointestinal Stromal Tumor on 68 Ga-NOTA-RM26 PET/CT.
- Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.
- Unraveling the site-specific features in small intestinal stromal tumors: a retrospective study.
- Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.
- Endoscopic hand suturing with clips for a large defect after endoscopic full-thickness resection of gastric gastrointestinal stromal tumor.
Trials on ClinicalTrials.gov1
Neuroblastoma
神经母细胞瘤Led 23 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 1
- Research papers it led
- 23
- Trials it led
- 1
- Share of China's trials
- 2.4%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- 18 F-MFBG PET/CT and MRI in Identifying Brain Metastases in a Posttreatment Neuroblastoma Patient.
- Comparing the role of different treatment modalities in locoregionally advanced olfactory neuroblastoma: The 20-year clinical experience of a single institution.
- [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.
- Shear wave elastography for differentiating parathyroid neoplasms with malignant diagnosis or uncertain malignant potential from parathyroid adenomas: initial experience.
- Proposal of a TNM classification-based staging system for esthesioneuroblastoma: More precise prediction of prognosis.
Trials on ClinicalTrials.gov1
Ewing sarcoma
尤文肉瘤Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
Multiple myeloma
多发性骨髓瘤Led 80 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 31
- Research papers it led
- 80
- Trials it led
- 51
- Share of China's trials
- 10.5%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis
- Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS St
- Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
- Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
- BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
Trials on ClinicalTrials.gov6
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- Isa-VRD in TIE HRMM
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- BR101 in Patients With Relapsed/Refractory Multiple Myeloma
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 15 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 12
- Research papers it led
- 15
- Trials it led
- 17
- Share of China's trials
- 6.7%
- Share of the world's papers
- 1.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.
- Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.
- Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.
- Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.
- Pneumocystis jirovecii Pneumonia Secondary to Blinatumomab Therapy: A Case Report.
Trials on ClinicalTrials.gov6
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Aplastic anaemia
再生障碍性贫血Led 71 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 10
- Research papers it led
- 71
- Trials it led
- 49
- Share of China's trials
- 50.5%
- Share of the world's papers
- 4.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.
- Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial.
- Adding recombinant human thrombopoietin to cyclosporine A and hetrombopag enhances the early hematologic response in transfusion-dependent non-severe aplastic anemia: a retrospective study.
- Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.
- Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.
Trials on ClinicalTrials.gov6
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
- Reproductive and Mental Health of Patients With Aplastic Anemia
- Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 10 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
- CHOP is insufficient for newly-diagnosed subcutaneous panniculitis-like T-cell lymphoma patients: a retrospective study of 32 patients in China.
- Disseminated tuberculosis complicated by intramuscular abscesses, meningoencephalitis, and hemophagocytic lymphohistiocytosis: a case report.
- Case Report: Missing zinc finger domains: hemophagocytic lymphohistiocytosis in a GATA2 deficiency patient triggered by non-tuberculous mycobacteriosis.
- Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.
Trials on ClinicalTrials.gov2
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Beta thalassaemia
β 地中海贫血Led 4 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.9%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 6
- Share of China's trials
- 12.8%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial.
- Analysis of genotypic distribution and rare variants of patients with α/β-thalassemia screened in one hospital in Beijing, China.
- Nrf2 expands the intracellular pool of the chaperone AHSP in a cellular model of β-thalassemia.
- Genome-wide analysis of pseudogenes reveals HBBP1's human-specific essentiality in erythropoiesis and implication in β-thalassemia.
Trials on ClinicalTrials.gov6
- β-Thalassemia Treatment With KL003 Cell Injection
- Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
- Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
- Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
- Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
- Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia
Haemophilia A
血友病 ALed 43 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 5
- Research papers it led
- 43
- Trials it led
- 8
- Share of China's trials
- 9.8%
- Share of the world's papers
- 1.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.
- Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
- The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.
- The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.
- Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.
Trials on ClinicalTrials.gov6
- Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
- ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- A Study of FVIII Gene Therapy for Hemophilia A
- Gene Therapy for Chinese Hemophilia A
- National Longitudinal Cohort of Hematological Diseases
- Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 1
- Share of China's trials
- 16.7%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led1
Fanconi anaemia
范可尼贫血Led 5 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 1
- Share of China's trials
- 50.0%
- Share of the world's papers
- 1.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.
- Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.
- Silencing of FANCI Promotes DNA Damage and Sensitizes Ovarian Cancer Cells to Carboplatin.
- Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.
- Zeylenone synergizes with cisplatin in osteosarcoma by enhancing DNA damage, apoptosis, and necrosis via the Hsp90/AKT/GSK3β and Fanconi anaemia pathway.
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 10 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 1
- Share of China's trials
- 1.3%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants.
- Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.
- Neuromyelitis optica spectrum disorders with recurrent syncope due to area postrema syndrome: a case report and literature review.
- Retinal structural and microvascular deterioration independent of optic neuritis in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders: An optical coherence tomography angiography study.
- Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder.
Trials on ClinicalTrials.gov1
IgG4-related disease
IgG4相关性疾病Led 47 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.1%).
- Open trials led
- 7
- Research papers it led
- 47
- Trials it led
- 21
- Share of China's trials
- 48.8%
- Share of the world's papers
- 4.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
- Genome-wide association studies reveal new insights into the genetic basis of IgG4-related disease in the Chinese Han population.
- Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients.
- Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease.
- Evaluating and predicting disease damage accumulation of IgG4-RD over ten years: utility of the IgG4-related Disease Damage Index.
Trials on ClinicalTrials.gov6
- Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
- Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
- A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
- National Registry of IgG4-RD in China
Myasthenia gravis
重症肌无力Led 6 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 1
- Share of China's trials
- 1.1%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Comorbidity of Myasthenia gravis and Graves' disease as immune reconstitution-associated autoimmune disease in HIV infection: A case report and literature review.
- Combined effect of thymectomy on myasthenia gravis in patients with concomitant auto-immune diseases: a 22-year single-center experience.
- Iron metabolism in non-anemic myasthenia gravis patients: A cohort study.
- Severe complications and management of a patient with myasthenia gravis undergoing anterior cervical spinal surgery: a case report.
- Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies.
Trials on ClinicalTrials.gov4
- Myasthenia Gravis Registry in China
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- A Prospective Cohort Study of Myasthenia Gravis in China
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Moyamoya disease
烟雾病Led 10 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Single-Cell Transcriptome Profiling Reveals Dynamic Cell Populations and Immune Infiltration in Moyamoya Disease.
- 5.0T MRA techniques for evaluating Moyamoya disease: 4D-ASL-MRA vs. 3D-TOF-MRA.
- Correlation between collateral compensation of the posterior cerebral artery on 5 T magnetic resonance imaging and clinical classifications in patients with Moyamoya angiopathy.
- Construction and Analysis of Immune Infiltration and Competing Endogenous RNA Network in Moyamoya Disease.
- Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Abundant infiltration of B cells and plasma cells in brain biopsy of a male patient with severe anti-NMDA receptor encephalitis: A case report.
- Anti-N-methyl-D-aspartate receptor encephalitis: characteristics and rapid diagnostic approach in the emergency department.
- The changing spectrum of antibody-mediated encephalitis in China.
Takayasu arteritis
大动脉炎Led 41 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 0
- Research papers it led
- 41
- Trials it led
- 1
- Share of China's trials
- 4.0%
- Share of the world's papers
- 5.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis.
- Validation and clinical application of 2022 ACR/EULAR criteria for Takayasu arteritis in a large Chinese cohort.
- Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis.
- Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis.
- Alterations of Gut Microbiome, Metabolome, and Lipidome in Takayasu Arteritis.
Trials on ClinicalTrials.gov6
- Pulmonary Artery Involvement in Takayasu's Arteritis
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
- The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
- Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis
- Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 28 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 28
- Trials it led
- 1
- Share of China's trials
- 1.4%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.
- Hypertension in idiopathic pulmonary fibrosis: evidence of immune and genetic links from clinical and genomic analyses.
- Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study.
- Clinical analysis of patients with idiopathic pulmonary fibrosis concurrent with surgery resectable lung cancer: a retrospective cohort study from perspective of ILD physicians.
- The impact of psoriasis on idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.
Trials on ClinicalTrials.gov6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
- 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 14 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (31.1%).
- Open trials led
- 0
- Research papers it led
- 14
- Trials it led
- 2
- Share of China's trials
- 100.0%
- Share of the world's papers
- 5.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Increased malignancy risk in patients with lymphangioleiomyomatosis: findings from a Chinese cohort.
- Associations of VEGF-D levels with clinical manifestations in lymphangioleiomyomatosis: a cross-sectional analysis of 631 cases.
- Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report.
- Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study.
- 68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTC-ASC lymphoscintigraphy: a prospective study.
Trials on ClinicalTrials.gov2
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 51 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 51
- Trials it led
- 1
- Share of China's trials
- 1.8%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis.
- Impacts of oral supplementation of vitamin B12 and plasma levels of homocysteine on progression and survival in a Chinese ALS cohort.
- Fasciculation in limbs serves as the predictor of ALS progression: an ultrasound study.
- Clinical and genetic characteristics of 1672 cases of amyotrophic lateral sclerosis in China: a single-center retrospective study.
- Dysregulated N6-methyladenosine modification in peripheral immune cells contributes to the pathogenesis of amyotrophic lateral sclerosis.
Trials on ClinicalTrials.gov1
Spinal muscular atrophy
脊髓性肌萎缩症Led 4 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (29.1%).
- Open trials led
- 1
- Research papers it led
- 4
- Trials it led
- 1
- Share of China's trials
- 3.3%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Effectiveness and Safety of Nusinersen Among Adults with 5q-Spinal Muscular Atrophy: A Multicenter Disease Registry in China.
- A perioperative nursing care protocol for patients with spinal muscular atrophy (SMA) type II or type III undergoing spinal surgery: a 4-year experience in 24 patients.
- Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study.
- Bone mineral density and its influencing factors in Chinese children with spinal muscular atrophy types 2 and 3.
Trials on ClinicalTrials.gov3
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Antisense Oligonucleotide for Spinal Muscular Atrophy
Fabry disease
法布雷病Led 4 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.3%).
- Open trials led
- 1
- Research papers it led
- 4
- Trials it led
- 1
- Share of China's trials
- 7.1%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Fabry Disease with Aseptic Meningitis: A Case Series and Literature Review of an Underestimated Clinical Presentation.
- Prevalence and Clinical Characteristics of Fabry Disease in Chinese Patients With Hypertrophic Cardiomyopathy.
- Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease.
- Anderson-Fabry disease: a rare phenocopy of hypertrophic cardiomyopathy.
Trials on ClinicalTrials.gov3
- Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
- A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
Duchenne muscular dystrophy
杜氏肌营养不良Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 3
- Share of China's trials
- 15.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD.
- Generalizable anchor aptamer strategy for loading nucleic acid therapeutics on exosomes.
- Identification and characterization of two DMD pedigrees with large inversion mutations based on a long-read sequencing pipeline.
- Forced activation of dystrophin transcription by CRISPR/dCas9 reduced arrhythmia susceptibility via restoring membrane Nav1.5 distribution.
Trials on ClinicalTrials.gov6
- A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
- A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy
- A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.
- Bisoprolol in DMD Early Cardiomyopathy
- Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
- Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Behçet disease
白塞病Led 56 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 2
- Research papers it led
- 56
- Trials it led
- 6
- Share of China's trials
- 35.3%
- Share of the world's papers
- 4.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Shelterin dysfunction promotes CD4+ T cell senescence in Behçet's disease.
- Proteomics Landscape Mapping of Organ-Resolved Behçet's Disease Using In-Depth Plasma Proteomics for Identifying Hyaluronic Binding Protein 2 Expression Associated With Vascular Involvement.
- Alterations of Gut Microbiome, Metabolome, and Lipidome in Takayasu Arteritis.
- Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou et al.
- Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome.
Trials on ClinicalTrials.gov6
- Baricitinib in the Treatment of Intestinal Behçet's Syndrome
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
- Pathogenesis of Intestinal Behcet's Syndrome
- Golimumab for the Treatment of Refractory Behcet's Uveitis
- Tocilizumab for the Treatment of Refractory Behcet's Uveitis
- Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
IgA nephropathy
IgA 肾病Led 7 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 1
- Share of China's trials
- 0.9%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Clinicopathological Features of Gitelman Syndrome with Proteinuria and Renal Dysfunction.
- The spectrum of kidney biopsy findings in Chinese HIV-infected patients.
- Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton.
- New biomarkers in IgA nephropathy.
- The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.
Trials on ClinicalTrials.gov1
Gaucher disease
戈谢病Led 1 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.7%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 1
- Share of China's trials
- 8.3%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Trials on ClinicalTrials.gov6
- A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
- Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
- Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
- Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
Osteogenesis imperfecta
成骨不全症Led 17 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 17
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 2.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
- Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
- The Spectra of Pathogenic Variants and Phenotypes in a Chinese Cohort of 298 Families with Osteogenesis Imperfecta.
- TBS as a complementary tool for assessing vertebral fractures and spinal deformity in children and adolescents with osteogenesis imperfecta.
- Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta.
Primary biliary cholangitis
原发性胆汁性胆管炎Led 24 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 1
- Research papers it led
- 24
- Trials it led
- 2
- Share of China's trials
- 4.0%
- Share of the world's papers
- 2.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China.
- Postpartum may be a risk factor for biochemical flares in patients with primary biliary cholangitis: A single-center experience.
- Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive.
- Clinical characteristics of primary biliary cirrhosis - idiopathic inflammatory myopathy overlap syndrome: A single center study.
- Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case-control study in China.
Trials on ClinicalTrials.gov5
- Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 6 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.0%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case-control study in China.
- Hepatocyte Mettl3 Deficiency Drives Primary Sclerosing Cholangitis and Liver Fibrosis via Cholangiocyte-Macrophage Crosstalk.
- Causal relationship between primary sclerosing cholangitis and systemic lupus erythematosus: a bidirectional Mendelian randomization study.
- Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA.
- Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma.
Congenital diaphragmatic hernia
先天性膈疝Led 5 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (18.3%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Development of a prediction nomogram for 1-month mortality in neonates with congenital diaphragmatic hernia.
- Pathological findings in congenital diaphragmatic hernia on necropsy studies: A single-center case series.
- Neuraxial anesthesia in ex utero intrapartum therapy for parturients with fetal congenital diaphragmatic hernia: a prospective observational study.
- Impact of the COVID-19 pandemic on congenital diaphragmatic hernia patients: a single-center retrospective study.
- Genetic Diagnosis and Clinical Features of Fetuses With Congenital Diaphragmatic Hernia.
Hirschsprung disease
先天性巨结肠Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 4 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.5%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Treatment progress of inherited epidermolysis bullosa.
- Excess KLHL24 Impairs Skin Wound Healing through the Degradation of Vimentin.
- Novel variants in LAMA3 and COL7A1 and recurrent variant in KRT5 underlying epidermolysis bullosa in five Chinese families.
- Two novel gene mutations cause different expressions of epidermolysis bullosa in Chinese patients.
Hereditary angioedema
遗传性血管性水肿Led 10 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (31.2%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Elevated level of circulating VEGF in Chinese patients with hereditary angioedema and its correlation with disease status.
- Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema.
- Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition).
- Proactive identification of rare diseases: lessons from hereditary angioedema diagnosis using electronic medical records.
- Hereditary Angioedema (HAE) in China: Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community.